BiotechTube

Mozobil + Mozobil + Mozobil

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Beta-Thalassemia

Conditions

Beta-Thalassemia

Trial Timeline

Oct 1, 2010 → Dec 1, 2014

NCT ID
NCT01206075

About Mozobil + Mozobil + Mozobil

Mozobil + Mozobil + Mozobil is a pre-clinical stage product being developed by Sanofi for Beta-Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01206075. Target conditions include Beta-Thalassemia.

What happened to similar drugs?

2 of 7 similar drugs in Beta-Thalassemia were approved

Approved (2) Terminated (0) Active (5)
✅DeferasiroxNovartisApproved
🔄deferasiroxNovartisPhase 3
🔄ICL670 + deferoxamineNovartisPhase 3
✅ICL670NovartisApproved
🔄CTX001Vertex PharmaceuticalsPhase 3
🔄CTX001Vertex PharmaceuticalsPhase 3
🔄CTX001Vertex PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01206075Pre-clinicalCompleted

Competing Products

18 competing products in Beta-Thalassemia

See all competitors
ProductCompanyStageHype Score
ACE-536MerckPhase 2
42
DeferasiroxNovartisApproved
43
Zoledronic acid + PlaceboNovartisPhase 2/3
34
deferasiroxNovartisPhase 3
40
ICL670 + deferoxamineNovartisPhase 3
40
DeferasiroxNovartisPhase 2
35
DeferasiroxNovartisPhase 2
35
ICL670NovartisApproved
43
BitopertinRochePhase 2
35
Luspatercept + PlaceboBristol Myers SquibbPhase 2
39
CTX001Vertex PharmaceuticalsPhase 3
44
CTX001Vertex PharmaceuticalsPhase 3
47
CTX001Vertex PharmaceuticalsPhase 2/3
38
CTX001Vertex PharmaceuticalsPhase 3
47
Deferitrin (GT56-252) + desferoxamine (DFO)SanofiPhase 1/2
32
REGN7999 + PlaceboRegeneron PharmaceuticalsPhase 2
42
VIT-2763 60 mg QD + VIT-2763 60 mg BID + VIT-2763 120 mg BID + PlaceboLabCorpPhase 2
24
VIT-2763 once a day (QD) + VIT-2763 twice a day (BID) + PlaceboLabCorpPhase 2
32